43:06

WCG Avoca Podcast Episode 39

24:58

Top 10 KRIs

11:29

Key Considerations for Setting up Studies in Central Monitoring

11:04

Implementing RBQM for Phase 1 Clinical Trials

14:43

How does Central Monitoring Differ Between Early and late Phase Trials

13:52

Final How do we identify and assess patients at risk

14:59

Final Do you trust data enough to make a decision

25:00

Day 1 Intro and Data Quality, what it is and why is it so important

22:55

Data Quality in Observational Research

17:42

How does Monitoring Drive Quality and Efficiency?

15:37

The participant journey in DCTs

13:10

What do the regualtory authorities really want to see

23:50

What roles and structures are required for end-to-end quality management?

14:58

What does a good Risk Assessment look like?

15:37

Learnings from the WHO Solidarity Findings

20:59

Intro to Day 2 of RBQM Ops 2022 and presentation on Central Monitoring in Early Phases

14:58

What does a good Risk Assessment look like?

17:25

How is monitoring driven by data source and collection?

17:35

How to deal with missing data and outliers in observational clinical studies

20:59

ICH E6 and E8 Quality Continuum

22:31

E8R1 What You Need to Know and Practical Advice on How to Implement it 1

06:34

RBQM Ops 2022 Why Did We Develop OPRA

27:00

Risk Assessment Series Webinar 5 Risk Communication and Beyond 2022

19:01

Risk Assessment Series Webinar 4 Risk Controls 2022

20:48

Risk Assessment Series Webinar 3 Risk Evaluation 2022

22:32

Risk Assessment Series Webinar 2 Identifying Risk 2022

15:22

Risk Assessment Series Webinar 1 Identifying Critical Variables

16:19

Stats Basics - Getting to know your Data

38:48

The 5 Big Quality Challenges

25:37

ICH E8(R1) - What You Need to Know and Practical Advice on How to Implement It

02:44

ICH E8(R1) and E6(R3) Quality Continuum explained in less than 3 minutes

02:04

What are the big industry issues that OPRA5 addresses?

01:41

Why we developed OPRA 5 - Reason # 2 - Duncan Hall

01:31

Why we developed OPRA 5 - Reason # 1 - Duncan Hall

01:46

Why we developed OPRA 5 - Reason # 3 - Duncan Hall

06:39

Why we developed OPRA 5 - Duncan Hall

22:45

Identifying Risks in Clinical Trials - Macarena Sahores

57:52

2020 RBQM review and predictions for 2021

07:35

5 Minutes 5 Questions - Christian Buhlmann - PSI

07:14

5 Minutes 5 Questions - Adam Samson - Curebase

13:19

5 Minutes 5 Questions - Jennifer Stewart - Premier Research

06:25

5 Minutes 5 Questions Suzanne Kincaid - Aperio Clinical Outcomes

00:37

TRI GCP e-learning trailer

00:41

TRI Risk Assessment & Controls e-learning trailer

12:31

5 Minutes 5 Questions - Melisa Williamson - Pharm Olam

07:28

MCC TRI Covance Interview Dec 2019 Part 1 Introductions and Sector Challenges

10:29

MCC TRI Covance Interview Dec 2019 Part 2 Technology People and Processes

07:38

MCC TRI Covance Interview Dec 2019 Part 3 Implementation and Change Management

07:53

MCC TRI Covance Interview Dec 2019 Part 4 Key Risk Indicators

04:01

MCC TRI Covance Interview Dec 2019 Part 5 Study Set Up

07:53

MCC TRI Covance Interview Dec 2019 Part 6 Quality Tolerance Limits

06:30

MCC TRI Covance Interview Dec 2019 Part 7 Evolving Technology and the Big Data Challenge

06:27

MCC TRI Covance Interview Dec 2019 Part 8 Measuring Success

33:49

CV 19 webinar #9

07:55

5 Minutes 5 Questions - Melissa Nezos - Firma

09:41

5 Minutes 5 Questions Marcia Swank - TFS

43:32

COVID-19 Webinar #7 - Change Management & Culture - life in the 90% economy

09:22

5 Minutes 5 Questions - Rosie McKellar - Worldwide Clinical Trials

34:42

COVOID-19 Webinar #6 - Reducing the fragility of your clinical trials

28:54

Clinical trial Risk Management is a multi dimensional problem - Free Webinar